Adjuvant nivolumab data published in NEJM show DFS benefit in bladder cancer
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs…
“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W.…
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…
Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses (CRs) in three-fourths of patients with BCG unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, according…
Neal D. Shore, MD, shares what he’s most looking forward to at this year’s American Urological Association Annual Meeting.
UroViu’s portable and versatile disposable cystoscopy platform delivers consistent performance, on par with reusable scopes, advancing clinical care, and limiting disposable waste. The benefit of…
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have…
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year